In the high-stakes landscape of hematological oncology, few diagnoses carry as much weight as acute myeloid leukemia (AML) characterized by FLT3 gene mutations. Known for its aggressive nature, poor prognosis, and a stubborn tendency to relapse, this subset of AML has long challenged the limits of modern medicine. However, a landmark study from the University of Hong Kong (HKUMed) has unveiled a promising new strategy: a dual-action combination therapy known as QUIZOM.
By pairing a targeted FLT3 inhibitor with a protein synthesis inhibitor, researchers have not only achieved an impressive 83% remission rate in clinical trials but have also unlocked a deeper understanding of how to outmaneuver the drug-resistant cells that typically drive cancer recurrence. Published in the journal Nature Communications, this discovery marks a significant pivot point in the pursuit of more effective, durable treatments for high-risk blood cancers.
The Challenge of FLT3-Mutated AML
Acute myeloid leukemia is a fast-growing cancer of the blood and bone marrow. Among its various genetic iterations, FLT3 mutations are the most prevalent, occurring in approximately 30% of cases. These mutations act as a "gas pedal" for cancer cells, fueling their rapid proliferation and making them notoriously difficult to eradicate.
For decades, the standard of care has been chemotherapy, followed—if possible—by hematopoietic stem cell transplantation (HSCT). While HSCT remains the only curative path for many patients, it is a physically demanding procedure. Patients must achieve a stable state of remission before they are physically fit enough to undergo the transplant. The problem, historically, has been the high failure rate of induction therapies; many patients simply do not reach the "clean" state required for surgery, or their leukemia returns too quickly to allow for a successful transplant window.
While conventional FLT3 inhibitors have provided temporary relief, they have consistently failed to offer a permanent solution, leaving the medical community in search of a strategy that could bridge the gap between initial diagnosis and successful transplantation.
The QUIZOM Chronology: From Concept to Clinical Trial
The development of QUIZOM is the result of years of meticulous research led by Professor Anskar Leung Yu-hung, Chair Professor in the Department of Medicine at HKUMed. The research journey, which culminated in the Phase 2 clinical findings, can be broken down into several distinct phases:
- Pre-Clinical Foundation: Before moving to human subjects, the HKUMed team conducted extensive multi-omics mechanistic studies. They aimed to identify why standard therapies failed and how the synergy between specific inhibitors could "trap" cancer cells.
- Clinical Recruitment (2017–2020): Between November 2017 and September 2020, the team recruited 40 patients aged 23 to 81. All participants had FLT3-mutated AML that had proven refractory to, or had relapsed after, standard chemotherapy.
- The Treatment Protocol: Patients were administered the QUIZOM regimen, a combination of Quizartinib (an FLT3 inhibitor) and Omacetaxine Mepesuccinate (a protein synthesis inhibitor).
- Data Analysis: Following the trial, the team utilized single-cell gene expression profiling to observe the real-time impact of the drugs on both malignant cells and the patient’s immune system.
- Patent and Future Planning: Following the success of the trial, the team filed a patent related to PLD1 inhibition—a mechanism identified during the study as critical to overcoming drug resistance.
Supporting Data: By the Numbers
The clinical outcomes of the Phase 2 trial are striking, particularly given the patient cohort’s high-risk profile. The efficacy of the QUIZOM combination is reflected in the following metrics:
- Composite Complete Remission (CRc): Approximately 83% of the 40 participants achieved a CRc, a significant benchmark for patients previously considered treatment-refractory.
- Survival Rates: The median leukemia-free survival (LFS) reached 10 months, while the median overall survival stood at 12.9 months.
- Bridge to Transplant: Crucially, 13 patients were able to successfully progress to allogeneic HSCT after undergoing the QUIZOM protocol. This "bridging" effect is perhaps the most vital takeaway of the study, as it proves that the therapy effectively stabilizes the disease long enough for curative surgery.
The data suggests that QUIZOM does more than just kill cancer cells; it transforms the patient’s biological environment to favor long-term survival.
Unveiling the Mechanism: A Two-Pronged Attack
The brilliance of the QUIZOM therapy lies in its dual-action mechanism, which was uncovered through rigorous multi-omics analysis.
Disrupting Protein Metabolism
Leukemic cells are "protein-hungry." Because they replicate so rapidly, they place a massive demand on their internal protein synthesis machinery. By introducing Omacetaxine Mepesuccinate, the researchers effectively "starved" the cancer cells of the proteins they needed to fold and function. When paired with Quizartinib, which halts the FLT3 signaling pathway, the cancer cells are caught in a pincer movement.
Immune System Activation
Perhaps the most surprising finding was that QUIZOM does not act in isolation; it stimulates the patient’s own immune system. Single-cell gene expression profiling revealed that the treatment activated T-cells within the patients. This essentially turned the therapy into a form of immunotherapy, where the drug suppresses the tumor while simultaneously "training" the immune system to recognize and attack the remaining malignant cells.
Overcoming Resistance via PLD1
The team also addressed the "elephant in the room": relapse. In patients who eventually saw their cancer return, researchers identified a persistent sub-population of stem cell-like leukemic cells. These cells had developed a defense mechanism involving PLD1-mediated phospholipid metabolism. This metabolic pathway allowed the cells to maintain protein folding despite the drugs, acting as a "refuge" for the cancer to regrow. The study concluded that adding a PLD1 inhibitor to the regimen could effectively shut down this final escape route, a discovery that has now been patented for future clinical refinement.
Official Perspectives and Expert Insight
Professor Anskar Leung, the lead investigator, has emphasized that the goal of QUIZOM is not just to provide a temporary fix, but to change the trajectory of high-risk AML care.
"The QUIZOM combination therapy provides an effective and feasible treatment option for patients with FLT3-mutated AML who are unfit for conventional chemotherapy," Professor Leung noted. He highlighted that by achieving a higher remission rate, clinicians can move patients into the transplant phase much faster. "With post-transplant maintenance and monitoring, the majority of patients can achieve sustained remission," he added.
The medical community has received the findings with cautious optimism. For patients who were previously told their options were exhausted, the ability to qualify for a bone marrow transplant is a life-altering development. The research team’s decision to patent the PLD1 inhibition strategy signals a commitment to moving this from an academic study to a standardized, commercially available clinical protocol.
Implications for the Future of Oncology
The success of the QUIZOM study has far-reaching implications for how we treat aggressive hematological malignancies.
- The "Bridge to Cure" Model: This study reinforces the importance of "bridging" therapies. Instead of viewing every drug as a singular cure, researchers are increasingly focused on therapies that prepare the body for the ultimate curative intervention—in this case, HSCT.
- Precision Medicine via Multi-Omics: The use of single-cell gene expression profiling to identify exactly how cancer cells resist treatment represents the gold standard of modern precision medicine. It allows doctors to see the "hidden" architecture of the cancer.
- Metabolic Targeting: The discovery that PLD1-mediated metabolism is a key driver of resistance opens a new door in drug development. By targeting the metabolic "lifestyle" of cancer cells, rather than just their genetic mutations, researchers may be able to bypass drug resistance that has plagued leukemia treatment for years.
As the team moves forward with plans to refine the QUIZOM regimen and potentially integrate PLD1 inhibitors into the mix, the hematology community will be watching closely. For now, the combination of Quizartinib and Omacetaxine Mepesuccinate stands as a beacon of progress—a testament to what happens when sophisticated molecular analysis meets clinical determination.
While the path from a Phase 2 trial to widespread clinical implementation is complex, the results published in Nature Communications offer a clear, actionable roadmap. For those living with the daunting reality of FLT3-mutated AML, the QUIZOM therapy is more than just a new acronym; it is a vital window of opportunity where none existed before.
About the Author
